« Return to News | R&D Trends

Ipsen acquires Syntaxin

Monday, July 15, 2013 10:48 AM

Global pharmaceutical company Ipsen has acquired Syntaxin, a U.K.-based private life sciences company specialized in botulinum toxin engineering. Ipsen will pay $36.4 million up front, as well as up to $169 million in development and commercial milestones.

Syntaxin has experience in botulinum toxinbiology, supported by a patent portfolio with 75 granted patents and over 130 patents pending. Syntaxin and Ipsen started collaborating in 2010. In 2011, a global strategic partnership was entered to explore the discovery and development of new compounds in the field of recombinant botulinum toxins. Syntaxin has expertise in the discovery of new therapeutic candidates, while Ipsen applied its skills to pharmacological, preclinical and clinical assessment of the compounds.

Syntaxin has an R&D portfolio that exploits the diversity of botulinum toxins, including recombinant botulinum toxins with improved designs and properties. Dr. Keith Foster and Dr. John Chaddock, co-founders of Syntaxin, will join Ipsen to help build a toxin platform across the therapeutic areas of neurology, endocrinology and uro-oncology. Ipsen expects to achieve full integration by the end of the year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.